Please enable JavaScript to continue using this application.

Compare $VCYT vs $VKTX | Chartloom

Compare

$VCYT vs $VKTX

Veracyte Inc · Viking Therapeutics Inc

VCYT

Veracyte Inc

VKTX

Viking Therapeutics Inc

Compare $VCYT vs $VKTX

Comparing Veracyte Inc and Viking Therapeutics Inc

VCYTVeracyte Inc

VKTXViking Therapeutics Inc

VCYTVeracyte Inc

Market cap

$3.61B

P/E (TTM)

32.42x

Forward P/E (NTM)

24.66x

Forward P/S (NTM)

5.69x

Rev growth (TTM)

17.3%

YTD performance

6.7%

52W performance

28.9%

FCF yield

4.6%

VKTXViking Therapeutics Inc

Market cap

$3.33B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.5%

52W performance

-11.9%

FCF yield

-12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

VCYT

VKTX

Detailed metrics comparison

VCYT

Veracyte Inc

VKTX

Viking Therapeutics Inc

Market Cap

VCYT$3.61B

VKTX$3.33B

Enterprise Value

VCYT$3.31B

VKTX$3.20B

Price

VCYT$45.23

VKTX$28.51

P/E Ratio

VCYT32.42x

VKTXN/A

P/S Ratio

VCYT6.42x

VKTX0.00x

EV/Sales

VCYT5.89x

VKTX0.00x

EV/EBITDA

VCYT24.67x

VKTX0.00x

P/B Ratio

VCYT2.65x

VKTX9.38x

P/FCF Ratio

VCYT21.74x

VKTXN/A

EV/FCF

VCYT19.94x

VKTX-7.65x

PEG Ratio

VCYT0.10x

VKTXN/A

Forward P/E (NTM)

VCYT24.66x

VKTXN/A

Forward P/S (NTM)

VCYT5.69x

VKTXN/A

Revenue (TTM)

VCYT$562M

VKTX$0

Revenue Growth (YoY)

VCYT17.3%

VKTXN/A

Forward Rev Growth

VCYT11.4%

VKTX236.5%

Gross Margin (TTM)

VCYT71.7%

VKTX0.0%

Operating Margin (TTM)

VCYT19.6%

VKTX0.0%

EBITDA Margin (TTM)

VCYT22.5%

VKTX0.0%

Net Margin (TTM)

VCYT20.4%

VKTX0.0%

FCF Margin (TTM)

VCYT29.5%

VKTXN/A

Net Income (TTM)

VCYT$114M

VKTX$-535M

FCF (TTM)

VCYT$166M

VKTX$-418M

EPS (TTM)

VCYT$1.40

VKTX-$4.60

ROE (TTM)

VCYT8.6%

VKTX-9456.0%

ROA (TTM)

VCYT8.0%

VKTX-8274.0%

ROIC (TTM)

VCYT8.6%

VKTX-9456.0%

Cash

VCYT$300M

VKTX$126M

Debt

VCYT$0

VKTX$0

Net Cash/Debt

VCYT$300M

VKTX$126M

Current Ratio (TTM)

VCYT9.16x

VKTX4.72x

Quick Ratio (TTM)

VCYT8.60x

VKTX4.57x

Debt/Equity (TTM)

VCYT0.00x

VKTX0.00x

Debt/Assets (TTM)

VCYT0.0%

VKTX0.0%

Interest Coverage (TTM)

VCYTN/A

VKTXN/A

Net Debt/EBITDA (TTM)

VCYT0.00x

VKTX0.00x

Beta

VCYT2.00

VKTX0.69

52W Performance

VCYT28.9%

VKTX-11.9%

YTD Performance

VCYT6.7%

VKTX-19.5%

% from 52W High

VCYT-25.7%

VKTX-33.9%

% from 52W Low

VCYT53.6%

VKTX10.6%

Asset Turnover (TTM)

VCYT0.39x

VKTX0.00x

FCF Yield (TTM)

VCYT4.6%

VKTX-12.6%

Earnings Yield (TTM)

VCYT3.2%

VKTX-16.1%

Dividend Yield (TTM)

VCYTN/A

VKTXN/A

Rule of 40

VCYT46.8

VKTX0.0

EV/GP/RG

VCYT0.60

VKTXN/A

Ticker research

View VCYT research View VKTX research

Metric	VCYT Veracyte Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.61B	$3.33B
Enterprise Value	$3.31B	$3.20B
Price	$45.23	$28.51
P/E Ratio	32.42x	N/A
P/S Ratio	6.42x	0.00x
EV/Sales	5.89x	0.00x
EV/EBITDA	24.67x	0.00x
P/B Ratio	2.65x	9.38x
P/FCF Ratio	21.74x	N/A
EV/FCF	19.94x	-7.65x
PEG Ratio	0.10x	N/A
Forward P/E (NTM)	24.66x	N/A
Forward P/S (NTM)	5.69x	N/A
Revenue & Growth
Revenue (TTM)	$562M	$0
Revenue Growth (YoY)	17.3%	N/A
Forward Rev Growth	11.4%	236.5%
Profitability
Gross Margin (TTM)	71.7%	0.0%
Operating Margin (TTM)	19.6%	0.0%
EBITDA Margin (TTM)	22.5%	0.0%
Net Margin (TTM)	20.4%	0.0%
FCF Margin (TTM)	29.5%	N/A
Net Income (TTM)	$114M	$-535M
FCF (TTM)	$166M	$-418M
EPS (TTM)	$1.40	-$4.60
ROE (TTM)	8.6%	-9456.0%
ROA (TTM)	8.0%	-8274.0%
ROIC (TTM)	8.6%	-9456.0%
Financial Health
Cash	$300M	$126M
Debt	$0	$0
Net Cash/Debt	$300M	$126M
Current Ratio (TTM)	9.16x	4.72x
Quick Ratio (TTM)	8.60x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.00	0.69
52W Performance	28.9%	-11.9%
YTD Performance	6.7%	-19.5%
% from 52W High	-25.7%	-33.9%
% from 52W Low	53.6%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.39x	0.00x
FCF Yield (TTM)	4.6%	-12.6%
Earnings Yield (TTM)	3.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	46.8	0.0
EV/GP/RG	0.60	N/A
Ticker research	View VCYT research	View VKTX research

Valuation

P/E Ratio

VCYT

32.42x

P/S Ratio

VKTX

0.00x

VCYT

6.42x

EV/FCF

VKTX

-7.65x

VCYT

19.94x

Growth & revenue

Revenue Growth TTM

VCYT

17.3%

Forward Revenue Growth

VKTX

236.5%

VCYT

11.4%

Profitability & performance

Gross Margin

VCYT

71.7%

VKTX

0.0%

ROE

VCYT

8.6%

VKTX

-9456.0%

FCF Yield %

VCYT

4.6%

VKTX

-12.6%

52-Week Performance

VCYT

28.9%

VKTX

-11.9%

Detailed metrics comparison

VCYT

Veracyte Inc

VKTX

Viking Therapeutics Inc

Market Cap

VCYT$3.61B

VKTX$3.33B

Enterprise Value

VCYT$3.31B

VKTX$3.20B

Price

VCYT$45.23

VKTX$28.51

P/E Ratio

VCYT32.42x

VKTXN/A

P/S Ratio

VCYT6.42x

VKTX0.00x

EV/Sales

VCYT5.89x

VKTX0.00x

EV/EBITDA

VCYT24.67x

VKTX0.00x

P/B Ratio

VCYT2.65x

VKTX9.38x

P/FCF Ratio

VCYT21.74x

VKTXN/A

EV/FCF

VCYT19.94x

VKTX-7.65x

PEG Ratio

VCYT0.10x

VKTXN/A

Forward P/E (NTM)

VCYT24.66x

VKTXN/A

Forward P/S (NTM)

VCYT5.69x

VKTXN/A

Revenue (TTM)

VCYT$562M

VKTX$0

Revenue Growth (YoY)

VCYT17.3%

VKTXN/A

Forward Rev Growth

VCYT11.4%

VKTX236.5%

Gross Margin (TTM)

VCYT71.7%

VKTX0.0%

Operating Margin (TTM)

VCYT19.6%

VKTX0.0%

EBITDA Margin (TTM)

VCYT22.5%

VKTX0.0%

Net Margin (TTM)

VCYT20.4%

VKTX0.0%

FCF Margin (TTM)

VCYT29.5%

VKTXN/A

Net Income (TTM)

VCYT$114M

VKTX$-535M

FCF (TTM)

VCYT$166M

VKTX$-418M

EPS (TTM)

VCYT$1.40

VKTX-$4.60

ROE (TTM)

VCYT8.6%

VKTX-9456.0%

ROA (TTM)

VCYT8.0%

VKTX-8274.0%

ROIC (TTM)

VCYT8.6%

VKTX-9456.0%

Cash

VCYT$300M

VKTX$126M

Debt

VCYT$0

VKTX$0

Net Cash/Debt

VCYT$300M

VKTX$126M

Current Ratio (TTM)

VCYT9.16x

VKTX4.72x

Quick Ratio (TTM)

VCYT8.60x

VKTX4.57x

Debt/Equity (TTM)

VCYT0.00x

VKTX0.00x

Debt/Assets (TTM)

VCYT0.0%

VKTX0.0%

Interest Coverage (TTM)

VCYTN/A

VKTXN/A

Net Debt/EBITDA (TTM)

VCYT0.00x

VKTX0.00x

Beta

VCYT2.00

VKTX0.69

52W Performance

VCYT28.9%

VKTX-11.9%

YTD Performance

VCYT6.7%

VKTX-19.5%

% from 52W High

VCYT-25.7%

VKTX-33.9%

% from 52W Low

VCYT53.6%

VKTX10.6%

Asset Turnover (TTM)

VCYT0.39x

VKTX0.00x

FCF Yield (TTM)

VCYT4.6%

VKTX-12.6%

Earnings Yield (TTM)

VCYT3.2%

VKTX-16.1%

Dividend Yield (TTM)

VCYTN/A

VKTXN/A

Rule of 40

VCYT46.8

VKTX0.0

EV/GP/RG

VCYT0.60

VKTXN/A

Ticker research

View VCYT research View VKTX research

Metric	VCYT Veracyte Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.61B	$3.33B
Enterprise Value	$3.31B	$3.20B
Price	$45.23	$28.51
P/E Ratio	32.42x	N/A
P/S Ratio	6.42x	0.00x
EV/Sales	5.89x	0.00x
EV/EBITDA	24.67x	0.00x
P/B Ratio	2.65x	9.38x
P/FCF Ratio	21.74x	N/A
EV/FCF	19.94x	-7.65x
PEG Ratio	0.10x	N/A
Forward P/E (NTM)	24.66x	N/A
Forward P/S (NTM)	5.69x	N/A
Revenue & Growth
Revenue (TTM)	$562M	$0
Revenue Growth (YoY)	17.3%	N/A
Forward Rev Growth	11.4%	236.5%
Profitability
Gross Margin (TTM)	71.7%	0.0%
Operating Margin (TTM)	19.6%	0.0%
EBITDA Margin (TTM)	22.5%	0.0%
Net Margin (TTM)	20.4%	0.0%
FCF Margin (TTM)	29.5%	N/A
Net Income (TTM)	$114M	$-535M
FCF (TTM)	$166M	$-418M
EPS (TTM)	$1.40	-$4.60
ROE (TTM)	8.6%	-9456.0%
ROA (TTM)	8.0%	-8274.0%
ROIC (TTM)	8.6%	-9456.0%
Financial Health
Cash	$300M	$126M
Debt	$0	$0
Net Cash/Debt	$300M	$126M
Current Ratio (TTM)	9.16x	4.72x
Quick Ratio (TTM)	8.60x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.00	0.69
52W Performance	28.9%	-11.9%
YTD Performance	6.7%	-19.5%
% from 52W High	-25.7%	-33.9%
% from 52W Low	53.6%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.39x	0.00x
FCF Yield (TTM)	4.6%	-12.6%
Earnings Yield (TTM)	3.2%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	46.8	0.0
EV/GP/RG	0.60	N/A
Ticker research	View VCYT research	View VKTX research